Digital somatic mutation analysis

By encapsulating cells in droplets for nucleic acid amplification and sequencing, the method addresses the challenge of detecting genetic variations in cell populations, providing accurate single-cell analysis for personalized medicine.

JP7584801B2Active Publication Date: 2024-11-19BITBIOME INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021516286
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-04-26
Filing Date
2020-04-24
Publication Date
2024-11-19
Estimated Expiration
2040-04-24

AI Technical Summary

Technical Problem

Existing methods struggle to accurately detect genetic variations in cell populations, particularly in cancer tissues, as they fail to account for the heterogeneity and genetic diversity at the single-cell level, which is crucial for understanding tissue composition and drug sensitivity.

Method used

A method involving encapsulating cells in droplets, gelling them to form gel capsules, lysing the cells, and amplifying nucleic acids within these capsules to enable digital counting and sequencing of mutations, allowing for comprehensive analysis of genetic variations, including copy number variations and single-nucleotide variations.

Benefits of technology

Enables efficient and accurate detection of genetic mutations at the single-cell level, reducing amplification bias and allowing for precise evaluation of cell composition and function, facilitating personalized treatment strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007584801000007
    Figure 0007584801000007
  • Figure 0007584801000008
    Figure 0007584801000008
  • Figure 0007584801000009
    Figure 0007584801000009
Patent Text Reader

Abstract

The present disclosure provides a method for analyzing the composition of variations in a tissue, simply, at low cost, and / or with high precision. The method for analyzing the composition of cells in a tissue according the present disclosure comprises a step for assessing information about the sequence of cells from samples containing amplified nucleic acid derived from single cells in the tissue. This method enables assessment of the cell composition in a tissue simply at low cost when being carried out before whole genome sequencing, and enables improvement in precision since it is possible to conduct comparison of long gene sequences when information regarding the target to be analyzed is narrowed down from digital sequence information after whole genome sequencing is performed.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to the analysis of cell populations and can be used in fields such as biological research, medicine, and health care. [Background technology]

[0002] Cancer, brain tissue, and nervous tissue are composed of various cell types with different lineages and functions (Non-Patent Document 1: Woodruff, 1983). In particular, cancer tissue contains many tumor subclones because cells grow while acquiring new genomic mutations one after another. These subclones differ in morphology, proliferation, drug resistance, etc. due to differences in genetic information and epigenetic control. For example, it is known that mutations in the epidermal growth factor receptor (EGFR) gene cause lung cancer, and furthermore, sensitivity to gefitinib, an EGFR inhibitor, changes depending on the location of the gene mutation (Non-Patent Document 2: Paez et al., 2004). In addition to gene mutations, there are also gene regions that are naturally diverse, such as changes in chromosome ploidy and copy number polymorphism. Accurate detection of these gene diversities is essential for a detailed understanding of body tissues.

[0003] However, many of these genetic features cannot be detected by analyzing cell populations as a whole. Accurate measurement of these features requires understanding of somatic tissues at the single-cell level (Zonget et al., 2012). Therefore, the need for single-cell analysis has been emphasized in various fields. [Prior art documents] [Non-patent literature]

[0004] [Non-Patent Document 1] Woodruff, MF (1983). Cellular heterogeneity in tumors. British Journal of Cancer,47(5), 589-94.https: / / doi.org / 10.1038 / bjc.1983.96 [Non-Patent Document 2] Paez, JG, Janne, PA, Lee, JC,Tracy, S., Greulich, H.,Gabriel, S., … Meyerson, M. (2004). EGFR Mutations in Lung Cancer: Correlationwith Clinical Response to Gefitinib Therapy. Science,304(5676), 1497 LP-1500.Retrieved fromhttp: / / science.sciencemag.org / content / 304 / 5676 / 1497.abstract [Non-Patent Document 3] Zong, C., Lu, S., Chapman, AR, & Xie, XS (2012).Genome-wide detection of single-nucleotide and copy-number variations of a singlehuman cell. Science, 338(6114), 1622-1626. Summary of the Invention [Means for solving the problem]

[0005] As a result of their intensive research, the inventors have discovered a method for analyzing the cellular composition of a tissue, which includes a step of evaluating cellular sequence information (e.g., mutations) from a sample containing amplified nucleic acid derived from each individual cell in the tissue, which allows for cheap and easy evaluation of cellular composition when performed prior to whole genome sequencing, and which, after whole genome sequencing, enables comparisons of long gene sequences by narrowing down the information to be analyzed from the digital sequence information, thereby increasing accuracy, and have completed the present invention.

[0006] The present disclosure makes it possible to comprehensively read gene sequences that identify the characteristics of each cell from amplified polynucleotides prepared in parallel for each cell in a cell population (e.g., a tissue) containing a variety of cells, digitally count the cells in a sample one by one, and provide information on the cell composition as absolute quantities.

[0007] Examples of embodiments of the present disclosure include the following: (Item 1) A method for analyzing mutations in a tissue, comprising: The method comprises the step of identifying mutations in cells or cell-like structures from a sample containing amplified nucleic acid derived from each cell or cell-like structure in the tissue. (Item A) A method for analyzing mutations in a tissue, comprising: obtaining a nucleic acid sequence from each cell or cell-like structure in said tissue; and analyzing said collection of individually obtained nucleic acid sequences. (Item 2) The amplified nucleic acid derived from each of the cells or cell-like structures is A step of encapsulating cells or cell-like structures in droplets one cell or structure at a time using a sample containing the tissue; gelling the droplets to form gel capsules; immersing said gel capsule in one or more lysis reagents to lyse said cells, wherein a polynucleotide comprising said genomic DNA or a portion thereof is dissolved into said gel capsule and is retained within said gel capsule in a state where substances binding to said genomic DNA or a portion thereof have been removed; contacting the polynucleotide with an amplification reagent to amplify the polynucleotide within the gel capsule; 3. The method of any preceding claim, wherein the method is produced by a method comprising: (Item 3) A method according to any of the above items, characterized in that a suspension of the cells or cell-like structures is flowed through a microchannel and the suspension is sheared with oil to create the droplets encapsulating the cells or cell-like structures. (Item 4) The method according to any of the preceding items, characterized in that the gel capsule is formed from agarose, acrylamide, PEG, gelatin, sodium alginate, Matrigel, collagen or a photocurable resin. (Item 5) The method according to any one of the preceding items, characterized in that the lysis reagent is at least one selected from the group consisting of lysozyme, labiase, yatalase, achromopeptidase, protease, nuclease, zymolyase, chitinase, lysostaphin, mutanolysin, sodium dodecyl sulfate, sodium lauryl sulfate, potassium hydroxide, sodium hydroxide, phenol, chloroform, guanidine hydrochloride, urea, 2-mercaptoethanol, dithiothreitol, TCEP-HCl, sodium cholate, sodium deoxycholate, Triton X-100, Triton X-114, NP-40, Brij-35, Brij-58, Tween 20, Tween 80, octyl glucoside, octyl thioglucoside, CHAPS, CHAPSO, dodecyl-β-D-maltoside, Nonidet P-40, and Zwittergent 3-12. (Item 6) The method according to any of the preceding items, characterized in that the gel capsule is a hydrogel capsule. (Item 7) The method according to any one of the above items, wherein the step of amplifying the polynucleotide in the gel capsule is carried out by a constant temperature strand displacement amplification reaction for 10 to 60 minutes. (Item 8) The method according to any of the preceding items, further comprising a step of selecting a sample containing amplified nucleic acid to be analyzed from the samples containing amplified nucleic acid derived from each of the cells or cell-like structures. (Item 9) A method according to any of the preceding items, comprising a step of detecting a nucleic acid having a specific sequence in a sample containing amplified nucleic acid derived from each of the cells or cell-like structures. (Item 10) The method according to any of the preceding items, wherein the step of detecting a nucleic acid having a specific sequence comprises amplifying a nucleic acid having a specific sequence. (Item 11) The method according to any of the preceding items, wherein the mutation comprises a mutation involving a sequence change compared to a reference sequence. (Item 12) The method according to any of the preceding items, wherein the mutation comprises a base substitution, insertion or deletion. (Item 13) The method described in any of the preceding items, further comprising a step of obtaining genomic sequence data of each of the cells or cell-like structures from a sample containing amplified nucleic acid derived from each of the cells or cell-like structures. (Item 14) A method according to any of the preceding items, further comprising a step of selecting genomic sequence data to be analyzed from the genomic sequence data of each of the cells or cell-like structures. (Item 15) The method according to any of the preceding items, wherein the mutation includes a mutation that does not involve a change in sequence compared to a reference sequence. (Item 16) The method described in any of the above items, wherein the mutation comprises a copy number variation (CNV). (Item 17) The method of any of the preceding items, comprising using the genomic sequence data to identify mutations, including base substitutions, insertions or deletions. (Item 18) The method according to any of the preceding items, wherein the tissue is a tissue containing a tumor. (Item 19) The method according to any of the preceding items, wherein the tissue is human tissue. (Item 20) A system for analyzing mutations in a tissue, comprising: an amplified nucleic acid sample providing unit for providing a sample containing amplified nucleic acid derived from each cell or cell-like structure in the tissue; and a mutation identifying unit that identifies a mutation in a cell or cell-like structure. (Item 21) The amplified nucleic acid sample providing unit, A droplet encapsulation unit that encapsulates cells or cell-like structures in droplets one cell or structure at a time using a sample containing the tissue; a gel capsule forming unit that gels the droplets to form gel capsules; one or more lysis reagents; a cell lysis unit that lyses cells by immersing a gel capsule in one or more lysis reagents, the gel capsule storing one or more lysis reagents for lysing the cells, the cell lysis unit being configured such that a polynucleotide containing the genomic DNA of the cell or a portion thereof is dissolved in the gel capsule and a substance that binds to the genomic DNA or a portion thereof is removed and the polynucleotide is retained in the gel capsule; a polynucleotide amplification reagent for amplifying the polynucleotide in a gel capsule; 21. The system according to item 20, comprising: (Item 22) The system described in Item 20 or 21, wherein the composition evaluation unit includes a detection reagent or detection device for detecting a nucleic acid having a specific sequence in a sample containing amplified nucleic acid derived from each of the cells. (Item 23) The system described in Item 22, wherein the detection reagent or detection device comprises a nucleic acid amplification and sequencing device for amplifying and sequencing nucleic acid. (Item 24) The system described in any one of Items 20 to 23, wherein the composition evaluation unit further includes a genome sequence data acquisition unit that acquires genome sequence data of each of the cells from a sample containing amplified nucleic acid derived from each of the cells in the microbiome.

[0008] It is contemplated that the present disclosure may provide one or more of the above features in combinations other than those specifically described. Still further embodiments and advantages of the present disclosure will be recognized by those skilled in the art upon reading and understanding the following detailed description, if necessary. Effect of the Invention

[0009] The present disclosure enables the easy acquisition of whole genome information of body tissues and the efficient detection of genetic mutations.

[0010] In the case of gene mutation analysis by PCR, it is possible to use a part of the amplified DNA sample, and by performing sequencing after PCR and determining the partial sequence, the composition such as the number of mutated cells can be evaluated from the information of a specific gene sequence, which allows for a cheap and simple evaluation. When performing mutation analysis based on digital sequence data, the digital sequence data obtained by sequencing is used as the target, and the gene sequence to be used for gene mutation analysis can be extracted to create composition data. In this case, not only mutations accompanied by sequence changes, such as mutations such as base substitutions and deletions (single-nucleotide variations (SNVs)), but also copy number variations (CNVs) can be evaluated. [Brief description of the drawings]

[0011] [Figure 1] FIG. 1 shows a schematic diagram of the steps taken to prepare amplified DNA. [Diagram 2] FIG. 2 shows a schematic diagram of wet sequence screening. [Diagram 3] FIG. 3 is a schematic diagram of post-selection sequencing. [Figure 4] FIG. 4 is a schematic diagram showing the dry sequence screening steps. [Diagram 5] FIG. 5 is a schematic diagram showing the overall flow of somatic mutation analysis in the present disclosure. [Figure 6] Figure 6 is a schematic diagram showing an example of a microfluidic device design. The device has two inlets and one outlet. The two inlets are for aqueous solution and oil, respectively. At the cross section, the aqueous solution is partitioned by the oil, forming multiple droplets. [Figure 7] Figure 7 shows the encapsulation of a single cell in a gel droplet. The left image shows the encapsulation of a GM12878 cell observed with a high-speed camera, and the right image shows a GM12878 cell encapsulated in a droplet. [Figure 8]Figure 8 shows fluorescence images of droplets after MDA (Multiple Displacement Amplification) amplification. The left image shows droplets (green fluorescence) positive for genome amplification that show a spherical morphology. The right image shows the collapse of the droplet shape after genome amplification. [Figure 9] FIG. 9 shows the circularity of genome amplification positive droplets before and after MDA. [Figure 10] FIG. 10 shows quantification of DNA yield of secondary amplification products from genome amplification positive or negative droplets. [Figure 11] Figure 11 shows a comparison of genome amplification bias between conventional direct single-cell genome amplification and gel droplet-based single-cell genome amplification. The ΔCt value of each single-cell genome amplification was measured by comparing the Ct value of each sample with the bulk-extracted DNA sample. [Figure 12] FIG. 12 shows the circularity of droplets before the reaction of MDA (0 min), and after reaction times of 30 and 60 min. [Figure 13] Figure 13 shows a comparison of genome amplification bias between gel droplet-based single nucleus genome amplification with 10 min MDA reaction and 30 min MDA reaction. The ΔCt value of each single nucleus genome amplification was measured by comparing the Ct value of each sample with the bulk extracted DNA sample. [Figure 14] Figure 14 shows the quantification of DNA yield of the second amplification product by FACS sorting. All sorted amplified negative droplets had a yield of less than 1000 ng. 53 sorted amplified positive droplets had a yield of 1000 ng or more. [Figure 15] FIG. 15 shows electrophoresis of EGFR ex19 amplicons obtained from single nuclei amplicons derived from gel droplets. [Figure 16]Figure 16 shows Sanger sequence analysis of EGFR ex20 and 21 amplicons obtained from single nucleus amplicons derived from gel droplets. (a) Sequence of EGFR ex20 amplicon. (b) Sequence of EGFR ex21 amplicon. Top: Sequence obtained from single cell genome known to have wild type sequence at EGFR ex20 and 21. Bottom: Sequence obtained from single cell genome known to have mutant sequence at EGFR ex20 and 21. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] The present disclosure will be described below while showing the best mode. Throughout this specification, the expression of the singular form should be understood to include the concept of the plural form, unless otherwise specified. Therefore, the singular article (for example, in the case of English, "a", "an", "the", etc.) should be understood to include the concept of the plural form, unless otherwise specified. In addition, it should be understood that the terms used in this specification are used in the sense commonly used in the field, unless otherwise specified. Therefore, unless otherwise defined, all technical terms and scientific and technical terms used in this specification have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. In case of conflict, the present specification (including definitions) will take precedence.

[0013] The present disclosure relates to a method for analyzing somatic mutation composition, comprising assessing somatic mutations from a sample containing amplified nucleic acid from each cell in a somatic population.

[0014] (Definition, etc.) The following provides definitions of terms particularly used in this specification and / or explains basic technical content as appropriate.

[0015] As used herein, a "cell" refers to any particle that contains molecules containing genetic information and is capable of replicating (whether independently or not). As used herein, a "cell" includes cells of unicellular organisms, bacteria, cells derived from multicellular organisms, fungi, and the like.

[0016] As used herein, the term "cell-like structure" refers to any particle that contains molecules that have genetic information. As used herein, the term "cell-like structure" includes intracellular organelles such as mitochondria, nuclei, and chloroplasts, as well as viruses.

[0017] As used herein, a "biomolecule" refers to a molecule possessed by any organism or virus. Biological molecules may include nucleic acids, proteins, sugar chains, lipids, and the like. As used herein, a "biomolecule analog" refers to a natural or non-natural variant of a biomolecule. Biological molecule analogs may include modified nucleic acids, modified amino acids, modified lipids, modified sugar chains, and the like.

[0018] In this specification, "gel" refers to a state in which polymeric substances or colloidal particles in a colloidal solution (sol) form a network structure as a whole due to their interactions, and the solution loses fluidity while still containing a large amount of the liquid phase, which is the solvent or dispersion medium. In this specification, "gelation" refers to changing the solution into a "gel" state.

[0019] As used herein, the term "gel capsule" refers to a gel-like particulate structure capable of retaining cells or cell-like structures therein.

[0020] In this specification, "genetic analysis" refers to examining the state of nucleic acids (DNA, RNA, etc.) in a biological sample. In one embodiment, the genetic analysis may be one that utilizes a nucleic acid amplification reaction. Examples of genetic analysis, including the above, include sequencing, genotyping and polymorphism analysis (SNP analysis, copy number polymorphism, restriction fragment length polymorphism, repeat number polymorphism), expression analysis, fluorescence quenching probe (Quenching Probe: Q-Probe), SYBR green method, melting curve analysis, real-time PCR, quantitative RT-PCR, digital PCR, etc.

[0021] As used herein, the term "single cell level" refers to processing the genetic information contained in one cell or cell-like structure in a state where it is distinguished from the genetic information contained in other cells or cell-like structures. For example, when amplifying polynucleotides at the "single cell level," amplification is performed in a state where the polynucleotides in a certain cell and the polynucleotides in other cells can be distinguished from each other.

[0022] As used herein, "single-cell analysis" refers to the analysis of genetic information contained in a single cell or cell-like structure while distinguishing it from genetic information contained in other cells or cell-like structures.

[0023] As used herein, "nucleic acid information" refers to information about the nucleic acids contained in a cell or cell-like structure, including the presence or absence of a particular gene sequence, the yield of a particular gene, or the total nucleic acid yield.

[0024] As used herein, "identity" refers to sequence similarity between two nucleic acid molecules. Identity can be determined by comparing positions in each sequence that can be aligned for comparison.

[0025] As used herein, the term "tissue" refers to a collection of cells or cell-like structures arranged three-dimensionally with a certain rule. A plurality of tissues combine to form an organ with a certain function, but in the present disclosure, a "tissue" may also refer to a region that crosses a plurality of tissues. In addition to cells or cell-like structures, a tissue may contain other components such as extracellular matrix.

[0026] In this specification, the "type" of a cell or cell-like structure is a parameter indicating the classification of the cell or cell-like structure. A certain cell or cell-like structure may be classified into multiple types by multiple classifications. For example, from the viewpoint of whether a cell has point mutation A, there are types with point mutation A and types without point mutation A. In addition, from the viewpoint of whether a cell has insertion mutation B, there are types with B and types without insertion mutation B. It is possible to identify which type a cell is.

[0027] As used herein, "mutation" refers to a portion of a cell or cell-like structure that differs from other cells or cell-like structures in terms of genetic information. "Mutation" may include, but is not limited to, a difference from a reference sequence that is the genetic information of a cell or cell-like structure of a certain species.

[0028] As used herein, "composition" refers to information about the type of each cell in a tissue (e.g., whether it contains a mutation) or the amount of each type of cell contained, and also includes information about whether the tissue contains cells corresponding to certain types or the amount of such cells.

[0029] (Tissue analysis) In one aspect of the present disclosure, a method for analyzing the composition of cells in a tissue may be provided, comprising identifying sequence information in cells or cell-like structures from a sample containing amplified nucleic acid derived from each cell or cell-like structure in the tissue. A tissue is a heterogeneous collection of cells, and by identifying the type of each cell, it is possible to obtain information such as the proportion of cells having a certain type (continuous) as well as the presence or absence of a certain property in the tissue (0 or 1). In the present disclosure, the tissue may be a human tissue.

[0030] (Mutation Analysis) In one aspect of the present disclosure, a method for analyzing mutations in a tissue may be provided, comprising identifying mutations in cells or cell-like structures from a sample containing amplified nucleic acid derived from each cell or cell-like structure in the tissue. Since a tissue is a heterogeneous collection of cells, identifying mutations in each cell makes it possible to obtain information such as the presence or absence of a mutation in the tissue (0 or 1) as well as the proportion of cells having a mutation (continuous). In the present disclosure, the tissue may be a human tissue.

[0031] In one aspect of the present disclosure, a method for analyzing mutations in tissues can be provided, comprising the steps of obtaining nucleic acid sequences derived from each cell or cell-like structure in the tissue individually, and analyzing using a set of the nucleic acid sequences obtained individually.Even when the amount of nucleic acid per cell is small and nucleic acids derived from multiple cells are analyzed in a mixed state, it is common to use an amplification reaction, but even when attempting to amplify nucleic acids as a whole, such as by using random primers, it is known that the degree of amplification for each sequence is biased due to GC content, etc. When amplification is biased, it is difficult to measure the relative amount of cells having a specific sequence in a tissue.

[0032] (Single cell analysis) In the present disclosure, the nucleic acid sequence derived from each cell or cell-like structure may be obtained by any method. There are various methods for single cell analysis, but the genome of one cell has a mass of only a few femtograms in bacteria and a few picograms in animal cells (Gregory, TR, Nicol, JA, Tamm, H., Kullman, B., Kullman, K., Leitch, IJ, … Bennett, MD (2007). Eukaryotic genome size databases. Nucleic Acids Research, 35 (Database issue), D332-8. https: / / doi.org / 10.1093 / nar / gkl828). However, genome analysis using a next-generation sequencer requires a genome in nanogram units. Therefore, for the detection of multiple genome mutation sites and analysis such as whole genome sequencing, it is generally necessary to amplify the genome amount to nanogram units by performing PCR or whole genome amplification. As a whole genome amplification method, the MDA (Multiple Displacement Amplification) method is widely used (Non-Patent Document 4: Zhang et al., 1992). The MDA method is a method for continuously amplifying genomes using phi29 DNA polymerase and random primers, and is known to be an excellent method for whole genome amplification. In order to obtain nucleic acid sequences derived from individual cells or cell-like structures, these whole genome amplification reagents or PCR reagents are applied to individual single cells to amplify the genome, which can then be used for various analyses.

[0033] With the evolution of genome amplification methods and the falling cost of sequencing, it is becoming possible to detect gene mutations and copy number variations in tens to hundreds of single cells by whole-genome sequencing or exome sequencing from whole-genome amplification, or by sequencing from specific amplification by PCR.

[0034] The most basic platform for adding genome amplification reagents to single-cell genomes is to sort single cells into tubes using a micromanipulator or flow cytometry, and then manually add lysis reagents and whole genome amplification reagents to each tube (Babbe, H., Roers, A., Waisman, A., Lassmann, H., Goebels, N., Hohlfeld, R., … Rajewsky, K. (2000). Clonal Expansions of Cd8 +T Cells Dominate the T CellInfiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulationand Single Cell Polymerase Chain Reaction. The Journal of ExperimentalMedicine, 192(3), 393-404. https: / / doi.org / 10.1084 / jem.192.3.393). In this case, it is known that a large amplification bias occurs when whole genome amplification is performed in a reaction field that is too large for the single cell genome (Ning,L.,Li, Z., Wang, G., Hu, W., Hou, Q., Tong, Y., … He, J. (2015). Quantitativeassessment of single-cell whole genome amplification methods for detecting copynumber variation using hippocampal neurons. Scientific Reports, 5,11415.Retrieved from https: / / doi.org / 10.1038 / srep11415). It has been revealed that the state of replication in the early stages of the whole genome amplification reaction has a significant impact on the amplification bias, and it is said that the causes are the adsorption of single-cell genomes to the tube and the presence of primer dimers. As a result of the occurrence of amplification bias, samples of insufficient quality for genome analysis are mass-produced, which ultimately reduces the number of samples that can be used for analysis and increases the wasteful use of expensive reagents. Therefore, it may be preferable to adopt a single-cell analysis method that reduces the amplification bias. Although the applicable samples are limited, it is also possible to perform whole genome amplification by separating only cells in the M phase of cell division, which contain a large amount of genome.

[0035] It may be preferable to use a method that can efficiently perform cell lysis and whole genome amplification for a large number of single cells in a small reaction field. Microfluidics can be used in single cell analysis. Microfluidics is a technology that allows the flexible manipulation of solutions in micro- and nanoliter units in microfluidic devices that require microchannels and microcontainers. One example is droplet microfluidics. Compared to conventional tube manipulation, droplet microfluidics has the advantage of allowing precise manipulation and automation. In a μm-sized flow channel provided in a microfluidic device, a liquid layer is sheared by an oil layer, and pL-sized droplets are continuously generated in units of 1000 per second. Each droplet acts as an independent reaction field, so by making a solution containing cells into droplets in a microfluidic device, cells are encapsulated one by one in the droplets, and reactions can be performed independently on each cell. Furthermore, with the development of droplet manipulation technology, it is possible to perform complex reactions such as the fusion of genome-encapsulated droplets and PCR or other reaction reagent-encapsulated droplets, as well as the division and sorting of droplets individually (Brouzes, E., Medkova, M., Savenelli, N., Marran, D., Twardowski, M., Hutchison, JB, …Samuels, ML (2009). Droplet microfluidic technology for single-cell high-throughput screening. Proceedings of the National Academy of Sciences of the United Statesof America, 106(34), 14195-200. https: / / doi.org / 10.1073 / pnas.0903542106). Droplet microfluidics can perform various operations on cells at high throughput by creating droplets and encapsulating cells, which may be preferable in the present disclosure.

[0036] In some embodiments of the present disclosure, a single-cell analysis technique using droplet microfluidics can be used, for example, a technique for fusing droplets together without applying an electric charge to obtain single-cell whole genome amplification products in a massively parallel manner. These techniques enable high-precision single-cell analysis to be performed at high speed on a variety of samples, and can be said to be very useful for obtaining single-cell genomes of entire cell populations and comprehensive genome mutation analysis.

[0037] Furthermore, in the present disclosure, it may be preferable to use a single-cell analysis technique that simultaneously ensures throughput and simplicity. For example, the device that applies an electrical load to add barcodes and amplification reagents is very fine, and each laboratory uses a different mechanism, so only a limited number of laboratories can use it. It takes time to master the fusion mechanism that does not apply an electric charge. In addition, since the droplets are created by shearing in oil and are collected in a floating state in the oil, they cannot be applied to automatic separation by flow cytometry or the like. In addition, these methods do not allow the removal of reagents from the tube once they have been added. Some lysis reagents are known to have the effect of inhibiting whole genome amplification, and primer dimers increase the amplification bias, so the step of removing a reagent and adding the next reagent after each reaction may be preferable when performing high-precision whole genome amplification.

[0038] Commercially available single-cell analysis devices that aim to enable single-cell analysis in many laboratories may be used. When analyzing a single genomic mutation, these analysis devices can amplify the target site by PCR without performing whole-genome amplification. However, in order to obtain information on many mutations or full-length genome information from a single cell, it may be preferable to adopt a method that can perform whole-genome amplification.

[0039] In one preferred embodiment of the present disclosure, in order to easily obtain information on nucleic acids derived from individual cells from a large number of cells, nucleic acids derived from individual cells can be obtained by a method including the following steps: using a sample containing tissue, encapsulating cells one by one in a droplet; gelling the droplet to form a gel capsule; and immersing the gel capsule in one or more types of lysis reagents to lyse the cells, wherein a polynucleotide containing the genomic DNA of the cell or a part thereof is dissolved into the gel capsule and is retained in the gel capsule in a state in which substances binding to the genomic DNA or part thereof have been removed; and contacting the polynucleotide with an amplification reagent to amplify the polynucleotide in the gel capsule.

[0040] In one embodiment of the present disclosure, the step of contacting the polynucleotide with an amplification reagent to amplify the polynucleotide within the gel capsule can also amplify the polynucleotide while maintaining the polynucleotide in a gel state within the gel capsule.

[0041] In one embodiment, the droplets can be created by flowing a single cell through a microchannel and encapsulating the single cell by shearing the suspension with oil. In some embodiments, the gel capsule can be a hydrogel capsule.

[0042] The material of the gel capsule may include agarose, acrylamide, photocurable resin (e.g., PEG-DA), PEG, gelatin, sodium alginate, Matrigel, collagen, etc. The gelation of the droplets can be achieved by forming the droplets so that they contain the material of the gel capsules and cooling the droplets. Alternatively, gelation can be achieved by applying a stimulus such as light to the droplets. The material of the gel capsules can be included in the droplets, for example, by including the material of the gel capsules in a suspension of cells or cell-like structures.

[0043] The gel capsule may be a hydrogel capsule. As used herein, "hydrogel" refers to a water solvent or dispersion medium held by a network of polymeric materials or colloidal particles.

[0044] The lysis reagent may be at least one selected from the group consisting of lysozyme, labiase, yatalase, achromopeptidase, protease, nuclease, zymolyase, chitinase, lysostaphin, mutanolysin, sodium dodecyl sulfate, sodium lauryl sulfate, potassium hydroxide, sodium hydroxide, phenol, chloroform, guanidine hydrochloride, urea, 2-mercaptoethanol, dithiothreitol, TCEP-HCl, sodium cholate, sodium deoxycholate, Triton X-100, Triton X-114, NP-40, Brij-35, Brij-58, Tween 20, Tween 80, octyl glucoside, octyl thioglucoside, CHAPS, CHAPSO, dodecyl-β-D-maltoside, Nonidet P-40, and Zwittergent 3-12.

[0045] The number of cells or cell-like structures that can be targeted in the mutation analysis of the present disclosure may be any number of 2 or more, for example, 10 or more, 50 or more, 100 or more, 500 or more, 1000 or more, 5000 or more, 10,000 or more, 50,000 or more, 10,000 or more, 500,000 or more, 1 million or more, 5 million or more, or 10 million or more. The mutation analysis of the present disclosure may use information on nucleic acids derived from individual cells from a larger number of cells than that obtained using a conventional single-cell reaction system, for example, a 0.2 mL or 1.5 mL microtube reaction system.

[0046] In one embodiment of the present disclosure, a gel droplet technique can be adopted in which droplets are prepared using an agarose solution. This allows analysis to be performed in many laboratories without sacrificing throughput or accuracy. By preparing droplets using agarose and embedding a single cell inside, it is possible to perform single cell isolation culture, PCR, and the like within the droplet. In the present disclosure, the gel droplet is regarded as a reaction field with a mesh structure in which a single cell or a single cell nucleus is embedded, and a dissolution reagent or a whole genome amplification reagent is applied so as to pass through the mesh structure, making it possible to easily perform whole genome amplification and removal of the reagent within the droplet. The labor-intensive separation of single cell genome-embedded droplets may be automated using a commercially available flow cytometer.

[0047] (Pre-genome sequencing analysis) In the present disclosure, prior to performing an analysis of the total sequence information of individual cells or cell-like structures (e.g., genome sequencing), individual cell-specific detection and selection may be performed by referring to the structures or sequences of nucleic acids or other biomolecular structures prepared in parallel from various cells or cell-like structures. That is, the method may include a step of selecting a sample containing amplified nucleic acid to be analyzed from samples containing amplified nucleic acid derived from each cell or cell-like structure.

[0048] In one embodiment, selection can be based on the presence or absence of a specific gene sequence, the yield of a specific gene, or the total nucleic acid yield. In some embodiments, selection can be based on the presence or absence of a specific gene sequence. In some embodiments, selection can be based on the yield of a specific gene being higher or lower than a reference yield. In some embodiments, selection can be based on the total nucleic acid yield being higher or lower than a reference yield.

[0049] In certain embodiments, the presence or absence of a specific gene sequence is detected by a means selected from the group consisting of a reagent that specifically detects a specific gene sequence, agarose gel electrophoresis, microchip electrophoresis, PCR, qPCR, and gene sequencing (Sanger sequencing, NGS).In some embodiments, the reagent that specifically detects a specific gene sequence includes an antibody, a probe, a DNA-binding fluorescent dye, and a fluorescent dye-binding nucleotide.

[0050] In certain embodiments, specific gene yield or total nucleic acid yield can be measured by absorbance measurement, fluorometry, agarose gel electrophoresis, microchip electrophoresis.The method can include detecting nucleic acid having specific sequence in a sample containing amplified nucleic acid from each cell.Detecting nucleic acid having specific sequence can include amplifying and sequencing nucleic acid having specific sequence.

[0051] The evaluation of mutation composition can include determining the absolute number of each type of cell in tissue.By determining the type of mutation for each amplified nucleic acid from each cell, the absolute number of cells with each type of mutation can be determined.The type of cell can be determined, for example, by determining the presence or absence of a specific gene sequence.

[0052] (Analysis involving genome sequencing) The method of the present disclosure may include obtaining genomic sequence data of each cell or cell-like structure in a tissue from a sample containing amplified nucleic acid from the cell or cell-like structure. By obtaining genomic sequence data, it is possible to obtain information about each cell in the tissue not only as a sequence but also in terms of the function or characteristics of the sequence.

[0053] It is possible to select genome sequence data to analyze from the genome sequence data of each cell. Genomic sequence data contains a large amount of information, so limiting the amount to be processed leads to reductions in labor and time.

[0054] The selection may include evaluating the presence or absence of a specific gene sequence and / or the identity with a specific gene sequence. In some embodiments, the identity with a specific gene sequence can be evaluated by using BLAST or the like. In certain embodiments, the selection may be based on the presence or absence of a specific gene sequence, and the nucleic acid information may be sorted for each cell. In other embodiments, the selection may be based on the identity between a specific gene sequence and nucleic acid information derived from two or more cells, and the nucleic acid information may be sorted for each cell. In some embodiments, the selection may be performed when the identity is equal to or greater than a certain level, or when the identity is equal to or less than a certain level. In certain embodiments, the identity may be 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100%. In other embodiments, the identity may be 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, 9% or less, 8% or less, 7% or less, 6% or less, 5% or less, 4% or less, 3% or less, 2% or less, 1% or less, or 0%.

[0055] When genome sequence data is available, the evaluation of the mutation composition may be performed by comparing long gene sequences in each cell. The long sequences may be, for example, gene sequences extracted from de novo assembly data. Such comparison of long gene sequences may not only increase the accuracy of the evaluation, but also enable evaluation of the function in the tissue. For example, even if it is known that multiple types of cells exist, it may not be possible to understand the overall state of the tissue without individual information on the role and state of each type of cell, based on sequence information alone. However, based on gene information, it is possible to obtain information on the amount of cells having a specific activity (e.g., enzyme activity, drug sensitivity, tumorigenicity) in the tissue.

[0056] (mutation) In the present disclosure, it is possible to identify mutations in cells or cell-like structures in tissues. Mutations include mutations with sequence changes and mutations without sequence changes. Mutations with sequence changes include substitutions, insertions, deletions, inversions, translocations, and the like. Mutations without sequence changes include copy number variations, and the like. Mutations can be identified by comparing sequences based on methods known in the art.

[0057] In single-cell analysis, analysis based on partial sequences can obtain information on mutations in a predetermined portion of the sequence, but when it is unknown which portion the mutation will occur in, it is thought that it is possible to identify the unknown mutation by obtaining information on the entire sequence information (genome).

[0058] In addition, mutations accompanied by sequence changes can be identified based on sequence information, but when identifying mutations that do not involve sequence changes, it may be necessary to compare the abundance of identical sequences, and it may be preferable to perform equal amplification of nucleic acids for each cell or cell-like structure. For such amplification, the features described in the (Single Cell Analysis) section of this specification can be appropriately adopted.

[0059] Tissues that can be analyzed in the present disclosure include tumor tissue, nerve tissue, blood, bone marrow fluid, semen, peritoneal lavage fluid, etc. Even if a tissue is composed of morphologically uniform cells, it may be composed of genetically diverse cells, and the method of the present disclosure is useful in understanding the properties of each tissue based on the characteristics and functions of individual cells that cannot be captured by averaged data from a cell population.

[0060] Tissues that can be analyzed in the present disclosure may be derived from any organism, and examples of animals include vertebrates such as humans or non-human mammals (e.g., mice, rats, rabbits, sheep, pigs, cows, horses, cats, dogs, monkeys, and chimpanzees), birds, reptiles, amphibians, and fish, and invertebrates such as insects and nematodes. Examples of plants include rice, wheat, corn, potatoes, barley, sweet potatoes, buckwheat, Arabidopsis, Lotus japonicus, tomatoes, cucumbers, cabbages, Chinese cabbages, eggplants, sugarcane, sorghum, apples, tangerines, bananas, peaches, poplars, pine trees, cedar trees, angiosperms, gymnosperms, ferns, mosses, and algae. In one embodiment, human tissues can be the subject of analysis.

[0061] It is possible to identify the amount of cells with mutations that can be used as tumor markers, indicators of tumor malignancy, and indicators of tumor drug sensitivity in tumor tissue, indicators of neuropsychiatric disorders and peripheral neuropathy in nerve tissue, indicators of genetic disorders in germ cells, indicators of acute myeloid leukemia malignancy and drug sensitivity in blood cells, and safety evaluation in regenerative medicine. It is possible to obtain information such as the proportion of cells with mutations (continuous) as well as the presence or absence of mutations in tissue (0 or 1).

[0062] The obtained mutation information for each single cell can be used for the development of new treatments and drugs by elucidating the genetic heterogeneity in tumor tissues and hematological malignancies, and can also lead to improved stratification of cancer patients, selection of treatments, and monitoring of pathology. If the type of mutant cells can be determined before and after treatment and the composition ratio can be known, drugs can be administered to patients under appropriate application conditions. For example, applying this technology to perform the current cancer panel DNA analysis on a single cell basis will enable more precise selection of treatment methods.

[0063] The genomes of brain neurons are influenced by mutations that occur during somatic cell division, as well as brain-specific genomic polymorphisms such as chromosome number and retrotransposon transfer. It has also been suggested that these genomic polymorphisms are associated with psychiatric disorders.

[0064] Conventionally, gene polymorphisms have been investigated in the entire DNA extracted from tissues, but based on the genomic information obtained for each single cell as disclosed in this invention, it is possible to determine the ratio of mutant cells in nerves as cells and the mutation polymorphism of each cell. Such detailed information will lead to elucidation of the mechanism of the occurrence of genomic polymorphisms specific to nerve cells and understanding and control of the pathology of mental disorders.

[0065] In the past, when safety and quality evaluation of transplant tissues using ES cells or iPS cells for regenerative medicine was performed, gene polymorphisms were examined in the entire DNA extracted from the tissue, but based on the genome information obtained for each single cell as disclosed in this disclosure, it is possible to determine the mutant cell ratio in the transplant tissue as cells and the mutant polymorphisms of each cell. Such detailed information will lead to elucidation of the mechanism of genome polymorphism generation in transplant tissues, development of control methods to maintain safety, and quality evaluation.

[0066] (system) In another aspect of the present disclosure, a system for analyzing mutations in tissues may be provided, the system may comprise means for implementing a method or steps thereof comprising any of the features described in other sections herein.

[0067] The system may include an apparatus for amplifying polynucleotides in cells. The apparatus may be capable of amplifying polynucleotides in cells at a single cell level, among others. The apparatus may include a droplet generator for encapsulating cells or cell-like structures in droplets one cell or structure at a time; a gel capsule generator for gelling the droplets to generate gel capsules; a lysis reagent immersion unit for immersing the gel capsules in a lysis reagent; a removal unit for removing contaminants from the gel capsules; and / or an amplification reagent immersion unit for immersing the gel capsules in an amplification reagent. The system or apparatus may further include a sorting unit for sorting the gel capsules and storing the gel capsules in a storage container.

[0068] The system or device may optionally include reagents such as a medium for encapsulating the cells or cell-like structures, a gel encapsulant, a lysis reagent, an amplification reagent, a reagent for sequencing the nucleic acid (e.g., a polymerase, a primer set (which may include a barcode sequence), etc.) Reagents may be used that are known in the art in addition to those described elsewhere herein.

[0069] The device or system may further include a sequencing unit for sequencing the nucleic acid sequence in the polynucleotide amplified in the amplification reagent immersion unit. The sequencing unit may be provided integrally with the device or as a separate device in the system. The sequencing unit may be an instrument for performing Sanger sequencing, Maxam-Gilbert sequencing, single molecule real-time sequencing (e.g., Pacific Biosciences, Menlo Park, California), ion semiconductor sequencing (e.g., Ion Torrent, South San Francisco, California), sequencing by synthesis, pyrosequencing (e.g., 454, Branford, Connecticut), sequencing by ligation (e.g., SOLiD sequencing, Life Technologies, Carlsbad, California), sequencing by synthesis and reversible terminator (e.g., Illumina, San Diego, California), nucleic acid imaging techniques such as transmission electron microscopy, nanopore sequencing, and the like.

[0070] The system or device may include a means for detecting and measuring the amplified genes. For example, a flow cytometry device suitable for handling the gel capsule shape may be provided integrally with the device or as a separate device in the system. The means for detecting and measuring the amplified genes may include a means for performing a detection reaction (e.g., a thermal cycler and appropriate reagents) and / or a means for detecting a signal (e.g., a light sensor, a camera, and appropriate analytical means).

[0071] The system or device may include a calculation unit that may be configured to perform any information processing described elsewhere herein. The calculation unit may be provided integrally with the device, or may be provided as a separate device (computer) in the system. In another aspect of the present disclosure, a program for performing the information processing described elsewhere herein in the calculation unit and implementing the method of the present disclosure and a storage medium having the program recorded thereon may also be provided. The calculation unit may include such a program and / or a storage medium having the program recorded thereon, as necessary.

[0072] (kit) One aspect of the present disclosure provides a kit that can be used in the method of the present disclosure. In the present disclosure, a kit for analyzing mutations in tissues can be provided. The kit can include a gel capsule material, and the use of the gel capsule is advantageous for amplifying nucleic acids in cells or cell-like structures at a single cell level as described elsewhere herein, and can be used as described herein for analyzing mutations in tissues. The kit can include, for example, a gel capsule material and, if necessary, one or more reagents. The reagents may be those known in the art in addition to those described elsewhere herein.

[0073] A kit for analyzing mutations in tissue may include a lysis reagent. The lysis reagent may comprise at least one selected from the group consisting of lysozyme, labiase, yatalase, achromopeptidase, protease, nuclease, zymolyase, chitinase, lysostaphin, mutanolysin, sodium dodecyl sulfate, sodium lauryl sulfate, potassium hydroxide, sodium hydroxide, phenol, chloroform, guanidine hydrochloride, urea, 2-mercaptoethanol, dithiothreitol, TCEP-HCl, sodium cholate, sodium deoxycholate, Triton X-100, Triton X-114, NP-40, Brij-35, Brij-58, Tween 20, Tween 80, octyl glucoside, octyl thioglucoside, CHAPS, CHAPSO, dodecyl-β-D-maltoside, Nonidet P-40, Zwittergent 3-12. The lysis reagent is useful for obtaining amplified polynucleotides at the single cell level, particularly genome-wide amplification products.

[0074] The kit may include reagents for amplifying nucleic acids. Examples of the reagents for amplification include polymerase, a primer set (which may include a barcode sequence), a base mix, and a suitable buffer. The kit may include reagents used for sequencing nucleic acids (e.g., polymerase, a primer set (which may include a barcode sequence), and the like). For example, the kit may include reagents for amplifying and decoding specific genes in Sanger sequencing or NGS (polymerase, a primer set (which may include a barcode sequence), and others). The kit may also include reagents for detecting and measuring specific sequences, such as nucleic acid binding dyes and fluorescently labeled probes. Using these reagents, the presence or absence of specific sequences can be measured using an instrument (such as a flow cytometer) that detects and measures amplified genes.

[0075] (Preferred embodiment) In this disclosure, we focused on gel droplets made using agarose, and developed a simple, highly accurate, and massively parallel whole genome amplification method by making it into a highly permeable micro-reaction field. By encapsulating animal cells in gel droplets and adding reaction reagents, whole genome amplification of single cells was performed within the gel droplets. This made it possible to quickly obtain high-precision whole genome amplification products with little amplification bias. In addition, by actually using the amplified products, it was possible to detect genome mutations at multiple locations at the single cell level with high precision. With this method, it became possible to quickly and inexpensively detect genome mutations in a cell population and select cells with a target mutation by obtaining tens of thousands of single-cell whole genome amplification products and detecting genome mutations. It is expected that this method will be useful for comprehensive understanding of genome mutations in somatic tissues and detailed understanding of cells with target mutations, as well as for invention of cell lineages and disease acquisition mechanisms and clinical diagnosis associated with them.

[0076] (system) A system for analyzing mutations in tissues, comprising an amplified nucleic acid sample providing unit for providing a sample containing amplified nucleic acid derived from each cell or cell-like structure in the tissue, and a mutation identifying unit for identifying mutations in the cells or cell-like structures, can perform whole genome amplification of single cells in gel droplets. In this case, the amplified nucleic acid sample providing unit preferably includes a droplet encapsulating unit for encapsulating cells or cell-like structures in droplets one cell or structure at a time using a sample containing the tissue, a gel capsule generating unit for gelling the droplets to generate gel capsules, one or more types of lysis reagents, and a cell lysis unit for lysing the cells by immersing the gel capsules in the one or more types of lysis reagents, the gel capsules containing the one or more lysis reagents for lysing the cells, the cell lysis unit being configured such that a polynucleotide containing the genomic DNA of the cell or a portion thereof is dissolved in the gel capsule and is retained in the gel capsule in a state in which a substance binding to the genomic DNA or a portion thereof has been removed, and a polynucleotide amplification reagent for amplifying the polynucleotide in the gel capsule. Furthermore, the composition evaluation unit includes a detection reagent or detection device for detecting a nucleic acid having a specific sequence in a sample containing amplified nucleic acid derived from each of the cells, and the detection reagent or detection device includes a nucleic acid amplification and sequencing device for amplifying and sequencing the nucleic acid, so that a highly accurate whole genome amplification product with little amplification bias can be obtained at high speed. This system also enables detection of genome mutations at multiple locations with high accuracy at the single cell level.

[0077] All references cited herein, including scientific literature, patents, patent applications, and the like, are hereby incorporated by reference in their entirety to the same extent as if each was specifically set forth.

[0078] The present disclosure has been described above by showing preferred embodiments for ease of understanding. The present disclosure will be described below based on examples, but the above description and the following examples are provided for illustrative purposes only and are not provided for the purpose of limiting the present disclosure. Therefore, the scope of the present disclosure is not limited to the embodiments or examples specifically described in this specification, but is limited only by the scope of the claims. EXAMPLES

[0079] Examples of the present disclosure are described below. The specific reagents used were those described in the Examples, but equivalent products from other manufacturers (Sigma-Aldrich, Wako Pure Chemical Industries, Nakarai, R&D Systems, USCN Life Science INC, etc.) can also be used.

[0080] (Example 1: Preparation of agarose gel droplets) (Fabrication of microfluidic devices) Using the drawing software AUTOCAD, we designed a microfluidic device in which the aqueous solution is sheared by the oil in the cross structure of the flow channel to produce droplets (Figure 6). The width of the flow channel inside the device was 100 μm, and in the cross structure, the carrier oil side was 17 μm, and the aqueous solution side was 8.5 or 17 μm. Using a photomask, the flow channel was transferred to a glass substrate coated with a negative resist (SU-8 3050, MicroChem Corp., Newton, MA) to prepare a mold for device fabrication. A spin coater (MS-B150, Mikasa, Japan) was used to coat the resist on the glass substrate. The height of the flow channel was 50 μm for the device with a cross structure aqueous solution side flow channel width of 17 μm, and 30 μm for the device with a cross structure aqueous solution side flow channel width of 8.5 μm. Polydimethylsiloxane (PDMS; Sylgard 184: Dow Corning Corp., Midland, MI) was used to fabricate the microfluidic device. The fabricated microchannel made of polydimethylsiloxane was used to prepare droplets.

[0081] (Preparation of agarose gel droplets using a microfluidic device) A 1.5% agarose solution was prepared using agarose (SIGMA-ALDRICH, St. Louis, MO). Pico-Surf1 (2% in Novec7500) (hereafter referred to as "oil") was used as the oil for droplet production. The oil was placed in a pressure-controlled pump (Mitos P-pump, Dolomite, Royston, UK) and connected to the inlet of the microchannel. The oil and agarose solution were pumped and introduced into the device's channel. The agarose solution was sheared by the oil at the crossroads to produce droplets, which were observed using a high-speed camera (FHS-33, Flovel, Tokyo, Japan) (Figure 7, left). The droplets produced were collected in a 1.5 mL tube. Some of the collected droplets were observed using a microscope (BZ-X710, KEYENCE, Osaka, Japan) (Figure 7, right). The collected gel droplets were allowed to stand on ice for 15 minutes to cause gelation of the gel droplets.

[0082] (Water layer replacement and shape observation of gel droplets) The gel droplets prepared were floating in oil, and it was necessary to replace the oil layer with an aqueous layer before adding the lysis reagent or whole genome amplification reagent. First, the oil in the tube was removed as much as possible to replace the droplets with an aqueous layer. Next, 200 μL of a 1:9 mixture of 1H,1H,2H,2H-Perfluoro-1-octanol (SIGMA-ALDRICH, St. Louis, MO) and Novec7500 was added and mixed with the droplets by tapping to remove the oil adsorbed on the droplets. After centrifuging for 1 second in a tabletop centrifuge (Petit Change, WAKENBTECH CO., Kyoto, Japan) and removing the supernatant, a 1:9 mixture of 1H,1H,2H,2H-Perfluoro-1-octanol and Novec7500 was mixed in the same manner, centrifuged for 1 second in a tabletop centrifuge, and the supernatant was removed. Next, 500 μL of acetone (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) was added, mixed using a vortex mixer (Nissinrika Co., Tokyo, Japan), and centrifuged for 30 seconds in a tabletop centrifuge to remove the supernatant. 2-Propanol (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) was then added, and the mixture and removal procedures were repeated in the same manner. Finally, the gel droplets were suspended in 500 μL of DPBS. The process of mixing the droplet suspension and removing it by centrifugation was repeated three times to replace the gel droplets with the aqueous layer.

[0083] (Example 2: Whole genome amplification in gel droplets and evaluation of amplification bias) (Encapsulation of model animal cells in gel droplets) Human lymphoblastoid cells, GM12878, were used as a model cell. A mixture of FBS (Thermo Fisher Scientific, Waltham, MA) and Penicillin-Streptomycin Solution (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) was added to Advanced RPMI 1640 (Thermo Fisher Scientific, Waltham, MA) and cultured in liquid in flasks (NIPPON Genetics Co., Ltd, Tokyo, Japan). After 48 hours of culture, 90% confluent animal cells were harvested by centrifugation at 250 × g for 3 min at 4°C, suspended in DPBS, and the cell concentration was measured. The cells were then stained with SYBR Green (invitrogen, Carlsbad, CA). According to the measurement results, the cell suspension was adjusted to a concentration of 3,000 cells / μL, and then mixed 1:1 with a previously prepared 3% agarose solution. The agarose concentration of the mixed solution was 1.5%, the cell concentration was 1,500 cells / μL, and the encapsulation ratio when producing droplets with a particle size of 50 μm was 1 cell / drop. Droplets were produced using the prepared solution using a microfluidic device. The collected gel droplets were left to stand on ice for 15 minutes to gel the gel droplets.

[0084] (Whole genome amplification in gel droplets by MDA method) GM12878 was encapsulated using the method described above to prepare droplets with two particle sizes, 50 μm and 70 μm. The conditions were an agarose concentration of 1.5% and an encapsulation ratio of 0.1 cell / drop. After preparation, the aqueous layer was replaced using the method described above. Buffer D2 (1M DTT and Buffer DLB) included in the Repli-g Single Cell Kit (QIAGEN, Valencia, CA) was then prepared for the droplet suspension, and DNA was single-stranded by reacting at 40°C for 10 minutes. The tube after reaction was mixed with the reagents included in the kit in the same way, and reacted at 30°C for 3 hours to perform whole genome amplification. After whole genome amplification, the droplets were washed by adding 100 μL of DPBS, centrifuging for 1 minute, and removing the supernatant twice. DNA was then stained using SYBR Green, and the tube was washed three times with 100 μL of DPBS. Because some of the droplets that showed positive DNA amplification were deformed due to genome amplification, the circularity of the fluorescent droplets was measured using ImageJ based on the fluorescence images (Figures 8 and 9).

[0085] Example 3: Evaluation of amplification bias of single-cell whole genome amplification products The droplets containing the whole genome amplification products with a diameter of 70 μm prepared in Example 2 were sucked up one by one under a microscope using a micromanipulator (Microdispenser, Drummond Scientific Company, Broomall, PA) and transferred to a PCR tube (hereinafter, this operation is called picking). 20 droplets each with positive and negative DNA amplification were picked, Buffer D2 was added, and the mixture was reacted at 40 degrees for 10 minutes, and then the reagents other than the alkaline reagent were added and reacted at 30 degrees for 2 hours, and a second whole genome amplification was performed using the DNA in the droplet as a template (secondary amplification). After the secondary amplification, the amplification reaction was stopped by reacting at 65 degrees for 3 minutes, and the amplified genome was quantified using a Qubit fluorometer (Thermo Fisher Scientific, Waltham, MA) (Figure 10). Next, primers targeting loci on chromosomes 1 to 22 (Table 1) were designed with reference to previous studies (Leung et al., 2015) (Hosono et al., 2003). [Table 1-1] [Table 1-2]

[0086] Using nine quantified single-cell genomes, qPCR was performed using 10 ng of genome as a template and Power Up SYBR Green Master Mix (Thermo Fisher Scientific, Waltham, MA) as the enzyme, with the composition shown in Table 2. The qPCR conditions were 50°C for 2 minutes, 95°C for 2 minutes, 40 cycles (95°C for 3 seconds, 60°C for 30 seconds), and a StepOnePlus real-time PCR system (Applied Biosystems, City of Foster City, CA) was used. [Table 2]

[0087] As a control for the sample in which whole genome amplification was performed in droplets, nine GM12878 cells were picked directly without being encapsulated in droplets, and whole genome amplification was performed in a PCR tube to evaluate the amplification bias. In addition, non-amplified genomes were obtained from the GM12878 cell population using a genome extraction kit (DNeasy, QIAGEN, Valencia, CA), and qPCR was performed in the same manner to serve as a reference. The absolute value of the difference between the Ct value of each obtained single-cell genome and the Ct value of the extracted genome was calculated, and a box plot was created to compare the amplification bias of single-cell genomes obtained by MDA in gel droplets and genomes that were subjected to MDA without being encapsulated in droplets (Figure 11).

[0088] (Example 4: Gel Droplet Whole Genome Amplification of Cell Nuclei and Sorting by FACS) (Preparation of cell nuclei from cultured animal cells and encapsulation in gel droplets) The GM12878 cells used in Example 2 were subjected to a cell nucleation treatment. First, the cultured cells were collected and washed three times with 1 mL of DPBS. After washing, 500 μL of a lysis reagent was added to the cell pellet and reacted on ice for 5 minutes to dissolve the cell membrane. The composition of the lysis reagent was 10 mM Tris-HCl (invitrogen, Carlsbad, CA), 10 mM NaCl (SIGMA-ALDRICH, St. Louis, MO), 3 mM MgCl2 (SIGMA-ALDRICH, St. Louis, MO), 0.1% Nonidet TMP40 (Thermo Fisher Scientific, Waltham, MA). Then, 500 μL of DPBS containing 1% Bovine Serum Albumin (SIGMA-ALDRICH, St. Louis, MO) was added, and the mixture was centrifuged at 500 × g for 5 minutes at 4 °C to collect only the cell nuclei. The mixture was washed three times with DPBS containing 1% BSA in the same manner, and the cell concentration was measured using an animal cell counter. The cell nuclei concentration was adjusted to 14,000 cells / μL, and the mixture was mixed 1:1 with a 3% agarose solution to a concentration of 0.1 cells / drop when droplets with a particle size of 30 μm were prepared. From the prepared solution, 30 μm gel droplets were prepared and cells were encapsulated.

[0089] (Whole genome amplification time of cell nucleus-embedded droplets) To confirm whether droplet deformation in MDA in gel droplets changes depending on the degree of cell lysis, whole genome amplification was performed on the prepared nucleus-embedded droplets. First, in order to remove as many intranuclear components as possible, 0.1 mg / mL Proteinase K (Promega, Madison, WI) and 0.05% Sodium Dodecyl Sulfate (Thermo Fisher Scientific, Waltham, MA) were added, and the mixture was reacted at 40 degrees for 10 minutes, and then washed five times with 500 μL of DPBS before MDA. Four DNA amplification-positive droplets were picked from the samples reacted for 10 minutes and 30 minutes, and after secondary amplification, the amplification bias was measured by qPCR in the same manner as in Example 3 (FIG. 13).

[0090] (FACS sorting of gel droplets containing whole genome amplification products from animal cells) The gel droplets prepared by the above method and subjected to MDA reaction for 30 minutes were introduced into FACS Melody. 58 droplets with positive DNA amplification and 14 droplets with negative DNA amplification were sorted so that one droplet was sorted into each tube. After sorting, secondary amplification was performed and genome quantification was performed using Qubit.

[0091] (Gel droplet whole genome amplification and detection of genomic mutations in human lung cancer cells) Three types of human lung cancer cells, NCI-H358, H1975, and H1650, which have gene mutations in the ex19-21 region of the EGFR gene, were used as model cells (Table 3). They were cultured in the same manner as in Example 2, and 48 hours after the culture, 90% confluent animal cells were cultured with Gibco TM The cells adhering to the flask were detached by adding 500 μL of TrypLE Express Enzyme (Thermo Fisher Scientific, Waltham, MA) and incubating at 37°C for 5 minutes. After washing and cell counting, the concentration of the three types of cells was made uniform and mixed 1:1:1 to prepare a cell suspension containing equal amounts of the three types of cells. A 3% agarose solution was prepared, mixed 1:1 with the mixed cell suspension, and sealed in a droplet with a diameter of 70 μm at 0.1 cell / drop. After water layer replacement, MDA was performed, and 102 droplets with positive DNA amplification were picked after washing and staining. Three types of primers were designed to include the three gene mutations shown in Table 3 (Table 4), and PCR was performed with the three types of primers on the single-cell whole genome amplification product. The enzyme used was PyroMark PCR Master Mix (QIAGEN, Valencia, CA). The PCR conditions were 95°C for 15 minutes, 40 cycles (94°C for 30 seconds, 62°C for 30 seconds, 72°C for 30 seconds), and 72°C for 10 minutes. The presence or absence of deletion mutations in each single-cell genome was detected by agarose electrophoresis of the PCR products targeting the ex19 deletion mutation. In addition, the PCR products targeting the ex20 and 21 SNPs were sent to Fasmac Co., Ltd., and the base sequences of the PCR products were obtained by Sanger sequencing to detect the presence or absence of the two SNPs in the single-cell genome.

[0092] [Table 3] [Table 4]

[0093] (Whole genome amplification of mammalian cells in gel droplets) We verified that single cell lysis and whole genome amplification reactions could be performed within gel droplets by reacting GM12878 cells encapsulated in gel droplets with an alkaline reagent and an MDA reagent in sequence. As a result, DNA amplification-positive gel droplets (green fluorescence) were observed at the same rate (10%) as the encapsulation ratio (Figure 8, left). The DNA amplification-positive gel droplets showed clear brightness, suggesting that the amplified DNA was retained inside the droplets even after repeated centrifugation and vortex washing. However, in some of the DNA amplification-positive gel droplets, the droplet outline was distorted, and the DNA or cell components inside were observed to have leaked out (Figure 8, right). Therefore, we performed DNA amplification reactions for two particle sizes (50 μm and 70 μm) and measured the circularity after the DNA amplification reaction (Figure 9). When the droplet size was large (70 μm), there was little fluctuation in circularity and the shape was relatively stable, but when the original size was small (50 μm), the shape was significantly distorted. This decrease in droplet outline collapse was observed for the first time after the genome amplification reaction, and was therefore thought to be due to the influence of amplified DNA components. As mentioned above, the presence or absence of amplification can be easily distinguished by fluorescent observation, so even if the droplet shape is collapsed, it is possible to manually select amplified droplets under a microscope. However, when attempting to separate using FACS, it is expected that the unevenness of droplet size will affect sorting, so it is necessary to reduce the collapse of droplet shape as much as possible.

[0094] Next, to evaluate cross-contamination of amplified DNA due to the collapse of the gel droplet shape, 20 droplets each of DNA amplification positive and negative were manually picked, secondary amplification was performed, and the amount of amplified DNA was quantified (Figure 10). As a result, a final DNA amplification product of 5945 ± 1623 ng was obtained from the DNA amplification positive droplets. On the other hand, a final DNA amplification product of 11.85 ng ± 10.7 ng was obtained from the DNA amplification negative droplets. The difference in the final DNA yield was clear, and cross-contamination of amplified DNA was considered to be negligible. In addition, it was shown that single-cell genome amplification products can be reliably recovered by recovering DNA amplification positive droplets using fluorescence as an indicator.

[0095] (Example 5: Evaluation of amplification bias of gel droplet whole genome amplification products) In order to confirm whether the single-cell genome obtained from the gel droplets has sufficient quality as a genetic analysis sample, qPCR was performed targeting the loci on each chromosome 1 to 22 to evaluate the degree of amplification bias. Non-amplified genomes extracted from a cell population were used as a comparison, and the difference in Ct value during qPCR of the single-cell genome amplified product was evaluated as the magnitude of amplification bias (Figure 11). In the sample in which MDA reaction was performed directly in one tube from one cell without encapsulation in a gel droplet as in the conventional method, the amplification bias was large, with the difference between the maximum and minimum Ct values ​​being 3 or more at all chromosomal sites, and 6 or more at 15 sites. This means that there was a difference of 10 times or more in the degree of amplification between single-cell genomes at all sites, and a variation of 100 times or more at 15 sites. On the other hand, in the single-cell genome amplified product sample prepared using gel droplets, there were only 7 sites where the difference in Ct value exceeded 3, and 0 sites where it exceeded 6. From this, it was confirmed that the variation in genome amplification was 10 times or less at 15 sites. This result suggests that temporarily enclosing a single cell in a gel droplet environment and temporarily carrying out an amplification reaction in a microenvironment can significantly suppress bias in the final amplification product. Existing research has shown that in whole genome amplification reactions, the conditions of priming and replication at the beginning of the reaction have a significant impact on the magnitude of subsequent bias. In particular, in conventional PCR tube reactions, since a single cell is handled in a large volume of reaction solution, the effects of adsorption to the tube and primer dimers are significant. On the other hand, in gel droplets, DNA is held within the gel and diffusion is restricted, and components derived from primer dimers are mainly present outside the gel, and these are removed by washing. It is believed that these effects have eliminated the bias factors that were a problem in conventional reactions. Therefore, the effect of suppressing bias was obtained by separating and performing secondary amplification after the initial genome amplification reaction is completed in the gel and reaches a certain volume.

[0096] (Example 6: Whole genome amplification of nucleus-encapsulated gel droplets and evaluation of amplification bias) Since the phenomenon that a part of the gel droplet becomes distorted and deformed by the MDA reaction was confirmed in Example 4, the MDA reaction time was evaluated from two viewpoints, that is, the amplification bias and the degree of droplet deformation, in order to apply it to FACS sorting. First, we considered that the cause was diffusion due to dissolution of intracellular components, and investigated a method of removing cytoplasmic components in advance and encapsulating them as cell nuclei in droplets to proceed with the subsequent reaction.

[0097] After nucleus encapsulation, in order to remove components other than genomic DNA as much as possible, cell lysis was performed with Proteinase K and SDS before alkali treatment, and MDA reactions were performed for 10, 30, and 60 minutes. The circularity of the droplets before the reaction and after 30 and 60 minutes of reaction was measured, and it was confirmed that the deformation progressed as the reaction time was extended (Figure 12). Next, four DNA amplification-positive droplets were picked after 10 and 30 minutes of MDA reaction, and a bias check was performed by qPCR (Figure 13). A large amplification bias was confirmed in the droplets with a 10-minute MDA reaction time, but the amplification bias was the same as that of the gel droplet MDA product measured in Example 5 in the droplets with a 30-minute MDA reaction time, and it was confirmed that the amplification was homogeneous. From the above, it was decided that the subsequent nucleus encapsulation gel droplet MDA would be performed for a reaction time of 30 minutes as a condition that has an amplification bias suppression effect and reduces the degree of deformation of the gel droplets.

[0098] (Example 7: FACS sorting validation of gel droplet whole genome amplification products) (FACS sorting verification of gel droplets) (FACS sorting of nucleus-encapsulated gel droplet MDA products) The 30 μm nucleus-encapsulating gel droplets after 30 minutes of MDA reaction were introduced into the FACS, and DNA amplification-positive droplets and DNA amplification-negative droplets were sorted into tubes one by one, and quantified after secondary amplification (Figure 14). The yield of the tubes sorting DNA amplification-negative droplets was 1000 ng or less in all cases. When the sorting efficiency of DNA amplification-positive droplets was calculated based on 1000 ng as the standard, 53 tubes were confirmed to have genome amplification of 1000 ng or more, resulting in a sorting efficiency of 91%. The above experiments demonstrated that FACS sorting of cell nucleus gel droplet MDA products is possible with an efficiency of 90% or more.

[0099] (Detection of somatic genomic mutations at the single-cell level using model cells) Using gel droplet MDA, we attempted to detect multiple types of genomic mutations in approximately 100 single-cell genomes. Three types of lung cancer cells, H358, H1975, and H1650, were encapsulated in gel droplets at a 1:1:1 ratio, and MDA reactions were performed. After picking of DNA amplification-positive gel droplets, secondary amplification and genome quantification were performed. As a result of quantification of 102 single-cell genomes, genomes of 1000ng or more were confirmed in 96 tubes. It is thought that DNA amplification-positive droplets were not picked in six tubes due to problems with the picking technique, and sufficient amplification was not achieved. PCR targeting the mutation sites in ex19, 20, and 21 was performed on each of the 96 single-cell genomes that yielded a yield of 1000ng or more. Part of the results of agarose gel electrophoresis after PCR are shown in Figure 15. A previous study (Kawada et al., 2008) confirmed that two bands were detected in electrophoresis of genomes containing heterozygous deletions in EGFR ex19. Agarose gel electrophoresis revealed that 24 amplified products had two bands, and 72 amplified products had one PCR band, indicating that the 24 genomes were obtained from cells containing a deletion mutation in EGFR ex19.

[0100] Next, the base sequences of the EGFR ex20 and 21 region amplification products were obtained by Sanger sequencing. As a result of the experiment, the base sequences of 191 out of 192 regions were obtained. Combined with the amplification results of the Ex19 region, only one of the three regions (total of 288 regions) of the 96 single cell genomes that were obtained could not be amplified. This result means that the loss of genetic information due to the amplification bias of the gel droplet MDA products occurred at a frequency of 0.4% or less, once again proving that the amplification bias was sufficiently low. Next, SNP mutations were detected from the obtained base sequence waveform. In the T790M mutation of Ex20, one guanine was replaced by adenine, and in the L858R mutation of ex21, one adenine was replaced by cytosine. When analyzing heterozygous SNPs using the Sanger sequencing method, previous studies have confirmed that a diagram in which the waveforms of the wild type base and the mutant type base overlap is obtained (Pao et al., 2005). When the obtained base sequences were confirmed, the mutations T790M and L858R were observed simultaneously in 34 single-cell genomes, and the wild-type genome was observed in 61 single-cell genomes. A part of the base sequences is shown in Figure 16. The 34 single-cell genomes in which mutations were observed in ex20 and 21 were different samples from the 24 single-cell genomes in which a mutation was observed in ex19 by agarose gel electrophoresis. In summary, the proportion of each mutation detected was classified into three types as expected (Table 5). Since there was no genome in which the three mutations in Ex19 to 21 were observed simultaneously, it was found that there were no gel droplets containing the genomes of H1650 and H1975 simultaneously among the 96 droplets. This means that the doublets were present at a sufficiently low rate (1 / 20, and the doublet of H1650 and H1975 was 1 / 120) as per the theoretical value. These experiments demonstrated that by encapsulating a cell population containing multiple cell types in gel droplets and performing simple and highly accurate whole genome amplification, genome mutation analysis at the single-cell level can be performed with high efficiency.

[0101] [Table 5]

[0102] References Babbe, H., Roers, A., Waisman, A., Lassmann, H., Goebels, N., Hohlfeld, R., … Rajewsky, K. (2000). Clonal Expansions of Cd8 + T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction. The Journal of Experimental Medicine, 192(3), 393 - 404. https: / / doi.org / 10.1084 / jem.192.3.393 Bos, H. Van Den, Bakker, B., Spierings, D. C. J., Lansdorp, P. M., & Foijer, F. (2018). International Journal of Biochemistry and Cell Biology Single - cell sequencing to quantify genomic integrity in cancer. International Journal of Biochemistry and Cell Biology, 94(September 2017), 146 - 150. https: / / doi.org / 10.1016 / j.biocel.2017.09.016 Brouzes, E.,Medkova, M., Savenelli, N., Marran, D., Twardowski, M., Hutchison,J. B., …Samuels, M. L. (2009). Droplet microfluidic technology for single-cellhigh-throughput screening. Proceedings of the National Academy of Sciences ofthe United States of America, 106(34), 14195-200.https: / / doi.org / 10.1073 / pnas.0903542106 Chenghang Zong, Sijia Lu1, Alec R. Chapman, X. S. X. (n.d.). Genome-WideDetection of Single-Nucleotide and Copy-Number Variations of a Single HumanCell. Gao, Y., Ni, X., Guo, H., Su, Z., Ba, Y., Tong, Z., … Zhang, N. (2017).Single-cell sequencing deciphersa convergent evolution of copy numberalterations from primary to circulating tumor cells. Genome Research, 27(8),1312-1322.https: / / doi.org / 10.1101 / gr.216788.116 Gregory, T. R., Nicol, J. A., Tamm, H., Kullman, B., Kullman, K., Leitch,I. J.,… Bennett, M. D. (2007). Eukaryotic genome size databases. Nucleic AcidsResearch, 35(Database issue),D332-8. https: / / doi.org / 10.1093 / nar / gkl828 Hosokawa, M.,Nishikawa, Y., Kogawa, M., & Takeyama, H. (2017). Massivelyparallel whole genome amplification for single-cell sequencing using dropletmicrofluidics. Scientific Reports, 7(1), 3-4.https: / / doi.org / 10.1038 / s41598-017-05436-4 Hosono, S., Faruqi, A. F., Dean, F. B., Du, Y., Sun, Z., Wu, X., … Lasken, R.S. (2003). Unbiased whole-genome amplification directly from clinical samples.Genome Research, 13(5),954-964. https: / / doi.org / 10.1101 / gr.816903 Hou, Y., Wu,K., Shi, X., Li, F., Song, L., Wu, H., … Wang, J. (2015). Comparisonofvariations detection between whole-genome amplification methods usedinsingle-cell resequencing. GigaScience, 4(1), 1-16.https: / / doi.org / 10.1186 / s13742-015-0068-3 Kawada, I., Soejima, K., Watanabe, H., Nakachi, I., Yasuda, H., Naoki,K., …Ishizaka, A. (2008). An alternative method for screening EGFR mutation usingRFLP in non-small cell lung cancer patients. Journal of Thoracic Oncology,3(10), 1096-1103.https: / / doi.org / 10.1097 / JTO.0b013e318186fadd Kintses, B.,van Vliet, L. D., Devenish, S. R., & Hollfelder, F. (2010).Microfluidicdroplets: new integrated workflows for biological experiments.Current Opinion in Chemical Biology, 14(5),548-555.https: / / doi.org / 10.1016 / j.cbpa.2010.08.013Lan, F., Demaree, B., Ahmed,N., & Abate, A. R. (2017). Single-cell genome sequencing atultra-high-throughput with microfluidic droplet barcoding. NatureBiotechnology, 35(7), 640-646.https: / / doi.org / 10.1038 / nbt.3880 Leung, M. L.,Wang, Y., Waters, J., & Navin, N. E. (2015). SNES: Singlenucleus exome sequencing. Genome Biology, 16(1).https: / / doi.org / 10.1186 / s13059-015-0616-2Mazutis, L., Gilbert, J., Ung, W. L.,Weitz, D. A., Griffiths, A. D., & Heyman, J. A. (2013). Single-cellanalysis and sorting using droplet-based microfluidics. Nature Protocols,8,870. Retrieved from https: / / doi.org / 10.1038 / nprot.2013.046 Ning, L., Li,Z., Wang, G., Hu, W., Hou, Q., Tong, Y., … He, J. (2015).Quantitativeassessment of single-cell whole genome amplification methods fordetecting copynumber variation using hippocampal neurons. Scientific Reports,5,11415. Retrieved from https: / / doi.org / 10.1038 / srep11415 Paez, J. G.,Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., …Meyerson, M.(2004). <em> EGFR< / em> Mutations in LungCancer: Correlation with Clinical Response to Gefitinib Therapy. Science,304(5676),1497 LP-1500. Retrievedfromhttp: / / science.sciencemag.org / content / 304 / 5676 / 1497.abstract Pao, W.,Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M.F., …Varmus, H. (2005). Acquired resistance of lung adenocarcinomas to gefitiniborerlotinib is associated with a second mutation in the EGFR kinase domain.PLoSMedicine, 2(3), 0225-0235.https: / / doi.org / 10.1371 / journal.pmed.0020073 Shahi, P., Kim,S. C., Haliburton, J. R., Gartner, Z. J., & Abate, A. R. (2017).Abseq: Ultrahigh-throughput single cell protein profiling with dropletmicrofluidic barcoding. Nature Publishing Group, (November 2016), 1-12.https: / / doi.org / 10.1038 / srep44447 Sommer, L., Ma,Q., & Anderson, D. J. (1996). neurogenins, a Novel Family ofatonal-RelatedbHLH Transcription Factors, Are Putative Mammalian Neuronal Determination GenesThat Reveal Progenitor Cell Heterogeneity in the Developing CNS and PNS.Molecularand Cellular Neuroscience, 8(4),221-241.https: / / doi.org / 10.1006 / mcne.1996.0060 Woodruff, MF (1983). Cellular heterogeneity in tumors. British Journal of Cancer,47(5),589-94.https: / / doi.org / 10.1038 / bjc.1983.96 Wu, H., Zhang, X.-Y., Hu, Z., Hou, Q., Zhang, H., Li, Y., … Wu, S. (2016).Evolution and heterogeneity of non-hereditary colorectal cancer revealed by single-cell exome sequencing. Oncogene,36, 2857. Retrieved fromhttps: / / doi.org / 10.1038 / onc.2016.438 Zhang, L., Cui,

[0103] Example 8: Cancer Diagnosis (1) Collection of tumor samples Tumor tissue samples are collected by biopsy. The tissue is treated with enzymes to extract cell nuclei. If necessary, the target cell population is enriched using flow cytometry or other methods. In the case of hematological malignancies, blood is collected, the peripheral blood mononuclear cell fraction is purified, and if necessary, the target cell population is enriched using flow cytometry or other methods. (2) Obtaining single-cell genome information According to the procedures described in Examples 1-2 of the present specification, a single cell is encapsulated in a gel capsule. An amplified polynucleotide is prepared in the gel capsule. The gel capsule containing the amplified polynucleotide is recovered. Single cell genome information is obtained by genetic analysis of the amplified polynucleotide. (3) Analysis of information Genetic regions related to drug resistance to molecular targeted drugs are evaluated, and appropriate drug prescriptions are selected. This method can determine the genomic polymorphism of cells on a cell-by-cell basis, making it possible to detect mutant cells with low abundance in tumors, and to monitor how the mutant cell ratio differs and changes depending on the location and time of collection in the tissue. This method makes it possible to adjust the treatment method at any time according to the state of the tumor composition of each patient.

[0104] The single cell technology disclosed herein also enables non-invasive monitoring and early detection of cancer. For example, circulating tumor cells can be collected from blood samples, but only 1 to 50 cells can be obtained from one patient. For example, in the case of a patient with gastric cancer, biopsy itself is life-threatening, so the single cell technology disclosed herein can be used as a non-invasive monitoring method. In addition, the degree of heterogeneity between cancer cells and non-cancerous cells that make up the cancer can be determined, making it possible to find a correlation with survival rates.

[0105] Furthermore, the single-cell technology disclosed herein can analyze even extremely small amounts of cancer cells, making it possible to detect rare mutations associated with metastasis or chemotherapy.

[0106] (Example 9: Safety and quality assurance in regenerative medicine) (1) Collect tissue samples for transplantation A portion is taken from a tissue sample to be transplanted made from ES cells or iPS cells. The tissue is treated with enzymes to extract the cell nuclei. If necessary, the target cell group is concentrated using flow cytometry or other methods. (2) Obtaining single-cell genome information According to the procedures described in Examples 1-2 of the present specification, a single cell is encapsulated in a gel capsule. An amplified polynucleotide is prepared in the gel capsule. The gel capsule containing the amplified polynucleotide is recovered. Single cell genome information is obtained by genetic analysis of the amplified polynucleotide. (3) Analysis of information SNPs and CNVs are evaluated as genomic changes related to tumorigenicity. This method can determine the genomic polymorphism of cells on a cell-by-cell basis, making it possible to detect mutant cells with low abundance in tissues, and to monitor how the mutant cell ratio differs and changes depending on the differentiation induction from stem cells and purification method. This method makes it possible to guarantee the safety and quality of tissues used for transplantation.

[0107] (Example 10: Detection of chromosomal abnormalities in germline cells, preimplantation diagnosis, prenatal diagnosis) (1) Collect embryo tissue samples A portion of the early embryo blastocyst is collected. If fetal nucleated red blood cells are the target, fetal nucleated red blood cells are collected from maternal blood. (2) Obtaining single-cell genome information According to the procedures described in Examples 1-2 of the present specification, a single cell is encapsulated in a gel capsule. An amplified polynucleotide is prepared in the gel capsule. The gel capsule containing the amplified polynucleotide is recovered. Single cell genome information is obtained by genetic analysis of the amplified polynucleotide. (3) Analysis of information This method is used for preimplantation genetic diagnosis to select cells without severe mutations. SNPs and CNVs are evaluated as genomic changes related to severe genetic diseases. This method can determine the genomic polymorphism of individual cells, so it can detect mutant cells with low abundance. This method makes it possible to perform preimplantation genomic screening of embryos and prenatal diagnosis.

[0108] (Example 11: Analysis using various tissues) Various tissues are dispersed into individual cells by the method described in Leung, ML, Wang, Y., Waters, J., & Navin, NE (2015). SNES: Singlenucleus exome sequencing. Genome Biology, 16(1). Using the samples prepared by this procedure, nucleated cells are prepared by the method described in Example 4, and gel droplets are prepared and the cells are encapsulated.

[0109] Using cells derived from various tissues encapsulated in gel droplets, whole genome amplification and detection of genome mutations can be performed in the same manner as in Example 4.

[0110] (Note) As described above, the present disclosure has been illustrated using a preferred embodiment of the present disclosure, but the present disclosure should not be interpreted as being limited to this embodiment. It is understood that the scope of the present disclosure should be interpreted only by the scope of the claims. It is understood that a person skilled in the art can implement an equivalent scope based on the description of the present disclosure and technical common sense from the description of the specific preferred embodiment of the present disclosure. It is understood that the patents, patent applications and literature cited in this specification should be incorporated by reference to this specification as if the contents themselves were specifically described in this specification. This application claims priority to patent application 2019-85837 filed with the Japan Patent Office on April 26, 2019, and it is understood that the contents of the application itself should be incorporated by reference to this specification as if the contents were specifically described in this specification. [Industrial Applicability]

[0111] The present disclosure can be used in fields such as biological research, medicine, and health care. [Sequence List Free Text]

[0112] SEQ ID NOs: 1 to 44: Primers listed in Table 1 SEQ ID NOs: 45 to 50: Primers listed in Table 4

Claims

1. 1. A method for analyzing mutations in a tissue, comprising: Identifying mutations in cells or cell-like structures from a sample containing amplified nucleic acid derived from each cell or cell-like structure in the tissue, comprising: The mutations include mutations that do not result in a change in sequence compared to a reference sequence, amplified nucleic acid from each of the cells or cell-like structures, A step of using the tissue-containing sample and encapsulating cells or cell-like structures in droplets one cell or structure at a time; gelling the droplets to form gel capsules; immersing said gel capsule in one or more lysis reagents to lyse said cells, wherein a polynucleotide comprising said genomic DNA or a portion thereof is dissolved in said gel capsule and is retained in said gel capsule in a state where substances binding to said genomic DNA or a portion thereof have been removed; contacting the polynucleotide with an amplification reagent to amplify the polynucleotide within the gel capsule; , including producing by a method comprising: method.

2. The method of claim 1, characterized in that a suspension of the cells or cell-like structures is flowed through a microchannel and the droplets encapsulating the cells or cell-like structures are created by shearing the suspension with oil.

3. 3. The method of claim 1 or 2, wherein the gel capsule is formed from agarose, acrylamide, PEG, gelatin, sodium alginate, matrigel, collagen or a photocurable resin.

4. The method according to any one of claims 1 to 3, characterized in that the lysis reagent is at least one selected from the group consisting of lysozyme, labiase, yatalase, achromopeptidase, protease, nuclease, zymolyase, chitinase, lysostaphin, mutanolysin, sodium dodecyl sulfate, sodium lauryl sulfate, potassium hydroxide, sodium hydroxide, phenol, chloroform, guanidine hydrochloride, urea, 2-mercaptoethanol, dithiothreitol, TCEP-HCl, sodium cholate, sodium deoxycholate, Triton X-100, Triton X-114, NP-40, Brij-35, Brij-58, Tween 20, Tween 80, octyl glucoside, octyl thioglucoside, CHAPS, CHAPSO, dodecyl-β-D-maltoside, Nonidet P-40, and Zwittergent 3-12.

5. The method according to any one of claims 1 to 4, characterized in that the gel capsules are hydrogel capsules.

6. The method according to any one of claims 1 to 5, characterized in that the step of amplifying the polynucleotide in the gel capsule is carried out by an isothermal strand displacement amplification reaction for 10 to 60 minutes.

7. The method according to any one of claims 1 to 6, further comprising the step of selecting a sample containing amplified nucleic acid to be analyzed from the samples containing amplified nucleic acid derived from each of the cells or cell-like structures.

8. The method according to any one of claims 1 to 7, comprising the step of detecting a nucleic acid having a specific sequence in a sample containing amplified nucleic acid derived from each of said cells or cell-like structures.

9. The method of claim 8, wherein the step of detecting a nucleic acid having a specific sequence comprises amplifying a nucleic acid having a specific sequence.

10. The method of any one of claims 1 to 9, wherein the mutation comprises a mutation involving a sequence change compared to a reference sequence.

11. The method of claim 10, wherein the mutation comprises a base substitution, insertion or deletion.

12. The method of any one of claims 1 to 11, further comprising obtaining genomic sequence data of each of said cells or cell-like structures from a sample comprising amplified nucleic acid derived from each of said cells or cell-like structures.

13. The method of claim 12, further comprising the step of selecting genomic sequence data to analyze from the genomic sequence data of each of the cells or cell-like structures.

14. The method of any one of claims 1 to 13, wherein the mutation comprises a copy number variation (CNV).

15. The method of any one of claims 12 to 14, comprising using the genomic sequence data to identify mutations, including base substitutions, insertions or deletions.

16. The method of any one of claims 1 to 15, wherein the tissue is a tissue containing a tumor.

17. The method of any one of claims 1 to 16, wherein the tissue is human tissue.

18. A system for analyzing mutations in a tissue, comprising: an amplified nucleic acid sample providing unit for providing a sample containing amplified nucleic acid derived from each cell or cell-like structure in the tissue; and a mutation identifier for identifying a mutation in a cell or cell-like structure, The mutations include mutations that do not result in a change in sequence compared to a reference sequence, The amplified nucleic acid sample providing unit, a droplet encapsulation unit that encapsulates cells or cell-like structures in droplets one cell or structure at a time using a sample containing the tissue; a gel capsule forming unit that gels the droplets to form gel capsules; one or more lysis reagents; a cell lysis unit that lyses cells by immersing the gel capsule in one or more lysis reagents, the gel capsule storing one or more lysis reagents for lysing the cells, the cell lysis unit being configured such that a polynucleotide containing the genomic DNA of the cell or a portion thereof is dissolved in the gel capsule and is retained in the gel capsule in a state in which a substance that binds to the genomic DNA or a portion thereof has been removed; a polynucleotide amplification reagent for amplifying the polynucleotide in a gel capsule; Including, system.

19. The system described in claim 18, further comprising a composition evaluation unit, the composition evaluation unit including a detection reagent or detection device for detecting nucleic acid having a specific sequence in a sample containing amplified nucleic acid derived from each of the cells or cell-like structures.

20. 20. The system of claim 19, wherein the detection reagent or device comprises a nucleic acid amplification and sequencing device for amplifying and sequencing nucleic acids.

21. The system described in claim 18, further comprising a composition evaluation unit, the composition evaluation unit including a genome sequence data acquisition unit for acquiring genome sequence data of each of the cells or cell-like structures from a sample containing amplified nucleic acid derived from each of the cells or cell-like structures.

22. The system described in claim 19 or 20, wherein the composition evaluation unit further includes a genome sequence data acquisition unit for acquiring genome sequence data of each of the cells or cell-like structures from a sample containing amplified nucleic acid derived from each of the cells or cell-like structures.

Citation Information

Patent Citations

  • Methods for quantitating DNA using digital multiple displacment amplification

    US20160068899A1

  • MDA using bead oligonucleotide

    US20180371525A1